The TKI plus InO-based therapy for newly diagnosed Ph+ ALL successfully met the efficacy end point, achieving an 81% MR3+ rate within 2 courses with limited cycles of InO. The modified schema 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback